Abstract Nicotine, a main addictive compound in tobacco smoke, has been linked to promotion and progression of lung, head and neck, pancreatic, and breast cancers, but the detailed mechanisms of cancer progression remain elusive. Here, we show that nicotine induces the expression of galectin-3 (an anti-apoptotic b-galactosidebinding lectin) in breast cancer cell line and in primary tumors from breast cancer patients. Nicotine-induced up regulation of galectin-3 is due to an increased expression of a9 isoform of nicotinic acetylcholine receptor (a9nAChR), which activates transcription factor STAT3 that in turn, physically binds to galectin-3 (LGALS3) promoter and induces transcription of galectin-3. Intracellular galectin-3 increased mitochondrial integrity and suppressed chemotherapeutic-induced apoptosis of breast cancer cell.
Introduction
Smoking is estimated to account for approximately 4-5 million deaths worldwide and approximately 443,000 deaths each year in the United States alone [1, 2] . Nicotine, the main addictive component of tobacco smoke, has been shown to promote cell proliferation, angiogenesis, and epithelial-mesenchymal transition (EMT), leading to enhanced tumor growth and metastasis [2] [3] [4] . Moreover, nicotine has been shown to abrogate the beneficial effect of chemotherapeutic drugs by inhibiting apoptosis in lung cancer [5] . The effects of nicotine are usually mediated through the nicotinic acetylcholine receptors (nAChRs) that are expressed on a variety of neuronal and non-neuronal cells [2] . nAChRs are complex of five subunits (comprising of a2-a10 and b2-b4) forming homopentamers (neuronal nAChRs) or heteropentamers (muscle type nAChRs) to form a central ion channel. Nicotine mimics acetylcholine by binding as an agonist to a subunit of nAChRs and a7nAChR is found the major stimulator of cancer development and progression in vivo in many cancers [2] . In breast cancer cells, at least four different subunits (a5, a7, a9, and b4) of nAChRs are known, but nicotine exposure increases mostly the expression of a9nAChR [6] .
Signal transducer and activator of transcription 3 (STAT3) is a major transcription factor for mediating cytokine responses [7] . In response to cytokines and growth factors, STAT3 is phosphorylated at tyrosine 705 by receptor-associated Janus tyrosine kinases and then forms homo-or heterodimers that translocate to the cell nucleus, where it drives transcription by binding to specific sequences. Inactivation of STAT3 in experimental animals leads to the development of several pathologies including embryonic lethality [7] . STAT3 is constitutively activated in human tumor cell lines and primary tumors and its constitutive activation commonly suggests poor prognosis [8, 9] . Recent studies suggest that nicotine/cigarette smoke could activate STAT3 in various pathological models including cancer [10] [11] [12] .
Galectin-3, a member of at least fifteen b-galactosidebinding soluble lectins family is involved in tumor cell adhesion, angiogenesis, cancer progression, and metastasis [13] [14] [15] [16] . Galectin-3 expression in gastric, liver, lung, bladder, and head and neck cancers was significantly increased compared to the normal tissues, and correlated with the progression of clinical stages and formation of metastases [17] [18] [19] [20] . Interestingly, a change in cellular localization of galectin-3 was observed during progression of various cancers. Down-regulation of surface galectin-3 expression in colon and tongue cancers, with an increased cytoplasmic expression of galectin-3 at more advanced stages was reported [21, 22] . Several studies suggest that cytoplasmic galectin-3 inhibits apoptosis similar to Bcl-2 [23] [24] [25] . Resistance to apoptosis is not only essential for cancer cell survival but also for tumor progression. Conversely, secreted galectin-3 from tumor cell induces T cell apoptosis implicating a possible role in immune escape mechanism during tumor progression [16, 23] . Several recent studies highlighted the clinical and biological significance of increased galectin-3 expression in apoptosis resistance in cancer cells in connection to targeted cancer therapies and also documented therapeutic effects of synthetic carbohydratebased small molecule inhibitors of galectin-3 [26] [27] [28] [29] . However, studies examining the relevance of galectin-3 to nicotine and STAT3 or the possible roles of nAChR in the regulation of galectin-3 have not been reported to date.
Here we present evidence that nicotine promotes galectin-3 expression in breast cancer cells. Nicotine activated STAT3 through a9nAChR, which then promoted galectin-3 expression in breast cancer cells. Overexpression of galectin-3 promoted chemoresistance through a nicotine dependent anti-apoptosis and an enrichment of side populations with cancer stem cell-like properties.
Methods

Cell culture and cell transfection
The breast cancer cell line MCF-7 was obtained from (ATCC) and cultured in Dulbecco's modified Eagle's medium with 10 % fetal bovine serum (FBS) and antibiotics. Cells were maintained in a humidified incubator at 37°C in the presence of 5 % CO 2 . The transfection of cells was performed with TurboFect (Thermo Scientific) according to the manufacturer's instructions.
Antibodies and reagents
Antibodies against phospho-(Tyr 705 )-STAT3 and STAT3 were purchased from Cell signaling Technologies. Antibodies against TWIST1, a9-nicotinic acetylcholine receptor (a9nAChR), endo G, and galectin-3 were obtained from Aviva Systems Biology. Beta actin antibody was obtained from Sigma. Nicotine and staurosporine were purchased from Sigma. Mitotracker (mitochondrion selective probe) was obtained from Invitrogen. SiRNA of galectin-3 (Duplex no. 2, siSTABLE) beginning at nt 518, 5 0 -GCAAUACAAAGCUGGAUAAdTdT-3 0 (sense), 5 0 -P UUAUCCAGCUUUGUAUUGCdTdT-3 0 (antisense) was purchased from Dharmacon Research (Lafayette, CO). Galectin-3 MISSION shRNA Lentiviral Transduction Particles with target sequence CCGGGCTCACTTGTTG CAGTACAATCTCGAGATTGTACTGCAACAAGTGA GCTTTTT (Cat No. SHCLNV-NM_002306) was purchased from Sigma. Negative Control Mission shRNA Transduction Particles (Cat No. SHC002V) was obtained from Sigma. Human STAT3-specific shRNAs (shRNA1-STAT3, shRNA2-STAT3, shRNA3-STAT3) were synthesized from pLKO.1 vector as previously described [30] . Target sequences of shRNA1-STAT3 (ATCTCCTGACCTTATGATCCG) are located at the 3 0 UTR starting at nucleotide 3170 (Genbank accession no. NM003150). Target sequences of shRNA2-STAT3 (TTCTTGGGATTGTTGGTCAGC) and shRNA3-STAT3 (TTGATTCTTCGTAGATTGTGC) are located at the coding region starting at nucleotides 1663 and 728, respectively. Vector containing scrambled shRNA was used as a negative control. Corresponding negative shRNA for STAT3 is the empty vector. Mission endo-ribonuclease prepared siRNAs (esiRNAs) of a9nAChR (CHRNA9) are a heterogeneous mixture of siRNAs synthesized by in vitro transcription of a 425 bp gene specific dsRNA, followed by enzymatic digestion using RNaseIII (Cat No. EHU008481, Sigma). Mission esiRNAs of TWIST1 are a heterogeneous mixture of siRNAs synthesized by in vitro transcription of a 459 bp gene specific dsRNA, followed by enzymatic digestion using RNaseIII (Cat No. EHU151571, Sigma). Negative control siRNA (Cat No. SIC001) was purchased from Sigma. All gene-specific siRNAs/shRNAs knocked down the expression of the corresponding genes as validated on either RT-PCR or Western blot.
Western blot
Western blot analyses were performed as previously described [31] . Briefly the cells were lysed using Mammalian Cell Lysis kit (Sigma) that includes 250 mM TrisHCl, pH 7.5, 5 mM EDTA, 750 mM NaCl, 0.5 % SDS, 2.5 % Deoxycholic acid, 5 % Igepal, and Protease inhibitor cocktail. After centrifugation, the clear supernatant was separated by SDS-PAGE and immunoblotted with appropriate primary antibodies as indicated in the figure legends. Specific bands were detected with HRP conjugated antirabbit IgG (Cell Signaling) and Enhanced Chemiluminescence reagent (Thermo Scientific). Original gel images are presented and no editing of gel images was performed.
For a Western blot analysis of the breast cancer tissues (smoker and non-smoker), paraffin embedded tissue sections were deparaffinized with xylene for 10 min followed by hydration using 100, 95, and 70 % alcohol (5 min each), and finally washing with distilled water. Tissue samples were scraped using an aseptic needle followed by extraction of protein in 29 Laemmli sample buffer. Sample was boiled in 100°C for 10 min, centrifuged, and the clear supernatant was subjected to Western blotting.
RNA isolation and gene expression on quantitative real time polymerase chain reaction (qRT-PCR) and PCR micoarray Total RNA was extracted using the All-in-One Purification kit (Norgen Biotek Corporation) and quantified spectrophotometrically using the NanoDrop 2000 spectrophotometer (Thermo Scientific). The first strand cDNA synthesis was carried out using RT 2 First Strand Kit (SA Biosciences) using 4 lg of total RNA and oligo (dT) primers and PCR was performed with gene specific primers (a9nAChR: forward 5 0 -GACTGTTCGTTTCCCAGATG G-3 0 and reverse 5 0 -ACGAAGTTGGGAGCCGACATCA-3 0 ; galectin-3: forward 5 0 -CACGGTGAAGCCCAATGCA-3 0 and reverse 5 0 -GTGAGCATCATTCACTGCAACC-3 0 ). Primers for glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (used as housekeeping gene control) were: forward 5 0 -TTGCCATCAATGACCCCTTCA-3 0 and reverse 5 0 -CGCCCCACTTGATTTTGGA-3 0 . The expression of each gene was quantified by using the comparative Ct (DDCt) method as described in the Assays-on-Demand Users Manual (Applied Biosystems). The fold values (X) were calculated using the formula: X = 2(-DDCt), where the data for the sample and sham-treated cell (here, the calibrator being the sham-treated cells) were first normalized against variations of sample quality and quantity. The DDCt was determined using the formula: DDCt = DC(t) sample -DC(t)calibrator, where DC(t) sample = C(t) target gene of sample -C(t) reference, and DC(t) calibrator = C(t) target gene of calibrator -C(t) reference. The expression of the target genes was normalized to GAPDH and relative to the calibrator = 2(-DDCt). Gene expression analysis was also performed using Cancer Pathway Finder PCR array (SA Biosciences, Qiagen) and calculated according to the manufacturer's instructions.
Scratch-wound healing assay
Scratch-wound healing assay was performed as previously described with some modifications [32] . Biriefly, MCF-7 cells were seeded in a 6-well plate and cultured overnight to form confluent monolayers. The cell monolayer was replaced with serum-free medium for overnight and a wound was introduced into the monolayer using a pipette tip. After washing with serum-free medium, the denuded area was photographed (0 h). Cells were then cultured in serum-free medium in absence or in the presence of nicotine (100 lM) for 72 h and following washing with 19 phosphate-buffered saline [(PBS) 10 mM phosphate, 140 mM NaCl, pH 7.5] wound images were photographed. The numbers of migrated cells into denuded area of three different samples were counted. The results were expressed as mean cell number ± SD.
Chromatin immunoprecipitation (ChIP) assay
ChIP assay was performed as previously described with some modifications [33] . Briefly, soluble chromatin was prepared from a total of 2 9 10 7 MCF-7 cells that were untreated or treated with nicotine (100 lM). The chromatin solution was diluted tenfold with ChIP dilution buffer (1.1 % Triton X-100, 1.2 mM EDTA, 167 mM NaCl, 16.7 mM Tris-HCl, pH 8.1, 0.01 % SDS, inhibitors of protease and phosphatase), pre cleared with protein A beads that were pre-blocked with 2 lg of sheared salmon sperm DNA and pre-immune serum. The pre-cleared chromatin solution was immunoprecipitated with anti- Table 1 for details). Galectin-3, a9nAChR, (Tyr 705 )-phospho-STAT3, and TWIST1 were detected using specific antibodies on paraffin-embedded sections of the tumor as previously described [31] . Briefly, sections were deparaffinized with xylene followed by hydration with graded concentrations of ethanol and then with distilled water. Samples were subjected to antigen retrieval followed by washing with PBS and incubation in 3 % hydrogen peroxide to inhibit endogenous peroxidase. The tissue sections were blocked with 1 % bovine serum albumin (BSA) and incubated with the indicated primary antibody (1:100) in BSA for 1 h. After washing, the sections were incubated with HRP conjugated secondary antibody for 1 h and positive signals were visualized with the diaminobenzidine (DAB) substrate. The number of cells showing positive staining of galectin-3, a9nAChR, TWIST1 and phospho-(Tyr 705 )-STAT3 were scored independently and blindly in 3 different area of each slide and then data were expressed as mean ± SD, where *** p \ 0.001.
Side population (SP) study SP cells are analyzed by flow cytometer equipped with violet laser diode (VLD) and DyeCycle Violet (DCV) fluorescence is measured through blue and red band pass filter. Dual-parametric analysis of Forward scatter (FSC) versus side scatter (SSC) is the primary gate used to identify cells in the appropriate size range, and to eliminate debris. Cells falling in the primary gate are subsequently evaluated by analysis of SSC height versus SSC width, followed by FSC height versus FSC width, for doublet discrimination. Finally, the live, singlet cells are displayed in a dual parametric presentation of DCV red fluorescence (x axis) versus DCV blue fluorescence (y axis), and the location of the SP is determined based upon loss of the putative SP in a cohort population pre-incubated with verapamil. DyeCycle Violet blue and red fluorescence are plotted allowing visualization of low fluorescence ''tail'' of cells (called SP cells, represented in side pink box of the plot) relative to the much larger bulk of DyeCycle Violet stained cells. Side population (SP) of breast cancer cells has recently been shown to harbor stem cell-like properties with resistance to apoptosis [34] [35] [36] . For side population study, MCF-7 cells were removed from the culture dish with trypsin and EDTA (GIBCO BRL), washed, suspended at 10 6 cells per ml in DMEM containing 2 % Fetal calf serum (FCS) (staining medium), and pre-incubated in a 1.5-ml Eppendorf tube at 37°C for 10 min. Cells were then labeled in the same medium at 37°C for 30 min with 5 lM Vybrant DyeCycle Violet Stain (Molecular Probes), 
Varying stages of tissue specimens from breast cancer patients who smoked (30-40 packs per year) or never smoked were purchased from Pathology Biorepository and Research Core of the University of Maryland Greenebaum Cancer Center under approved Institutional Review Board protocol and were subjected to immuno-histochemical analyses ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor 2 either alone or in combination with 50 lM verapamil (Sigma) [an inhibitor of ABC transporters [34] [35] [36] . Then, 3-5 9 10 6 cells were analyzed using the Becton-Dickinson FACSVantage fluorescence-activated cell sorter.
Cell viability assays
Cell viability was quantified using commercially available WST-1 colorimetric kit (Roche). Cells were cultured in a clear bottom 96-well plate and the final volume of culture medium in each well was maintained 100 ll. After treating with various agents, 10 ll of WST-1 was added to each well of the plate incubated at 37°C for 2 h and absorbance at 450 nm was measured using an ELISA plate reader.
Apoptosis assay
Following treatment of MCF-7 cells (approximately 10,000) with siRNA (galectin-3 specific or negative control) for 24 h, cells were incubated with nicotine (100 lM, 48 h) plus staurosporine (STS, 1 lM for last 24 h). One set of cells received only staurosporine (1 lM for last 24 h). Cells were washed with ice cold PBS, stained with annexin-V FITC (Enzo Life Sciences) according to the manufacturer's instructions and analyzed by flow cytometry using FL1 channel within 30 min.
STS-induced DNA fragmentation of cells in the presence of nicotine alone or nicotine plus siRNA (galectin-3 specific or negative control) was assessed from the determination of cytoplasmic histone-associated DNA fragments (mono-and oligonucleosomes) using The Cell Death Detection ELISA PLUS kit (Roche Applied Science).
JC-1 staining
The JC-1 staining solution was prepared from the stock (MitoPT TM -JC1 Assay kit, Immunochemistry Technologies) by diluting the reagent 1:10 in the culture medium (DMEM). Cells (5 9 10 5 /ml) were plated in 6-well plate and treated with siRNAs, nicotine, and staurosporine, and diluted JC-1 staining solution (200 ll) was added to each well. Cells were grown at 37°C for an additional 30 min prior to harvesting and spectrofluorimetry (excitation at 480 nm). Healthy cells with functional mitochondria containing red JC-1 aggregates were detected at 590 nm. Apoptotic cells with collapsed mitochondria containing green JC-1 monomers were detected at 527 nm.
Mammosphere assay
Mammosphere culture was performed as previously described [37] with some modifications. Briefly, single-cell suspensions were plated (10,000 cells/well) in 6-well ultralow attachment plates (Corning) in mammocult medium (Stem cell Technologies) and cultured for 3 days. Mammosphere/Tumorspheres were counted using phase contrast microscope (Axioplane 2 Zeiss microscope fitted with a cooled CCD Olympus model DP70 camera).
Statistics
Data were expressed as mean ± SD unless otherwise mentioned. Comparisons were made between different treatments (analysis of variance) using the software GraphPad Prism 6 (GraphPad Software Inc., San Diego, CA), where an error protecting the multiple comparison procedure, namely Tukey-Kramer multiple comparison tests, was applied for the analysis of significance of all the data.
Results
Nicotine increases apoptosis resistance and cell migration
Nicotine was shown to increase apoptosis resistance and cell migration leading to tumorigenesis in breast cancer cells, particularly MCF-7 [34, 38, 39] . We used staurosporine (STS) (protein kinase inhibitor known to induce mitochondrion-dependent apoptosis) to examine the efficacy of nicotine in promoting resistance to MCF-7 cell death. Treatment of MCF-7 cells with 1 lM STS for 24 h induced significant cell death (69.4 %, p \ 0.001). Interestingly, nicotine protected cells from cell death in a dosedependent manner (8.7, 23.5, and 50 % protection with 1, 10, and 100 lM nicotine, respectively) (Fig 1a) . Nicotine alone at up to 100 lM concentration did not show any toxicity on MCF-7 cells (data not shown). Next, we evaluated the role of nicotine on cell migration. As 100 lM nicotine gave most chemoresistance to MCF7 cell without any toxicity on cell viability, we used 100 lM nicotine for most follow-up experiments.
Consistent with previous reports [38, 39] , in scratchwound healing assay nicotine-treated MCF-7 cells (100 lM, 72 h) increased cell migration by almost fourfold (p \ 0.001) compared to the untreated control cells (Fig. 1b, c) .
Nicotine increases expression of galectin-3
As galectin-3 was involved in tumor cell migration and metastasis [13] [14] [15] [16] , we evaluated the expression of galectin-3 in breast tissue specimens from cancer patients who smoked or never smoked by immunostaining with antigalectin-3 antibody [31] . Expression of galectin-3 (gal3) was significantly increased in a stage-dependent manner in (Fig. 2a, i , ii). Moreover, galectin-3 content was significantly (p \ 0.001) higher in all stages of breast cancer patients who smoked compared to those who never smoked (Fig. 2a, i , ii). This observation was corroborated by a Western blot analysis where expression of galectin-3 in breast cancer tissue specimen (stage III) from smoker was about twofold compared to that from a non-smoker matching tissue specimen (Fig. 2a, iii) . However, one cannot conclude that galectin-3 expression is induced by cigarette smoking on the basis of this finding. It is possible that smoking can affect the types of tumors that develop, which in turn are associated with the expression levels of galectin-3. Next, we investigated the effect of nicotine on galectin-3 expression in MCF-7 cells. A qRT-PCR analysis of the expression of LGALS3 mRNA showed a dosedependent increase (1.7-fold at 1 lM and fivefold at 100 lM of nicotine) (Fig. 2b) . The increased expression of galectin-3 protein in nicotine-treated MCF-7 cells was also confirmed by a Western blot analysis (Fig. 2c) .
a9nAChR directly modulates expression of galectin-3
As nicotine is known to induce the expression of a7nAChR in most cancers and a9nAChR in breast cancer, we quantified the levels of these two receptors using qRT-PCR. Nicotine treatment (100 lM, 48 h) induced only a9nAChR, but not a7nAChR (Fig. 3a) . The induction of a9nAChR in the nicotine-treated cells was further confirmed by a Western blot analysis (Fig. 3b) . To investigate if the tumors from smokers expressed higher amount of a9nAChR, tumor tissues from smoker and non-smoker groups were compared after immunostaining with an antia9nAChR antibody. a9nAChR positive cells were Table 1 significantly (p \ 0.001) higher in smokers than in nonsmokers (Fig. 3c) . Next, we investigated if a9nAChR was responsible for the nicotine-induced expression of galectin-3. Treatment of cells with nicotine in presence of a a9nAChR-specific siRNA did not result in an elevation of galectin-3 expression (Fig. 3d) . Thus, a9nAChR is required for nicotine-induced galectin-3 expression.
Galectin-3 suppresses apoptosis by blocking mitochondrial damage
As galectin-3 is known to exert anti-apoptotic response in cancer cells, we investigated the effect of nicotine and galectin-3 on cell death. MCF-7 cells were treated with 1 lM STS following stimulation with nicotine (100 lM) in presence or absence of galectin-3 siRNA as described in the ''Methods'' section. Similar experiment was also performed with gal3 shRNA transfected MCF-7 cells. The efficacy of either gal3 siRNA or shRNA to knockdown gal3 expression was investigated by RT-PCR or Western blot and expression of gal3 was found down-regulated with treatment of either gal3 siRNA (Fig. 4a ) or gal3 shRNA (Fig. 4b) . Nicotine blocked STS-induced cell death by almost 50 % (p \ 0.001), however, nicotine-treated cells regained their sensitivity to STS upon knocking down galectin-3 by either siRNA or shRNA (p \ 0.001) (Fig. 4c) . The cytoprotective effect of nicotine and galectin-3 on drug-induced cell death was further corroborated through annexin V binding (Fig. 4d) and cytoplasmic histoneassociated DNA fragmentation (Fig. 4e) . In annexin V Table 1 ) and smoked (5 patients) as determined by immunostaining with anti-a9nAChR antibodies. Adjacent bar graph shows quantitative expression of a9nAChR in these samples. Each sample was performed in duplicate or in triplicate. The number of cells showing positive staining of a9nAChR was scored independently and blindly in 3 different area of each slide and then data were expressed as mean ± S.D, where ***p B 0.001. d Effect of a9nAChR silencing on the expression of galectin-3. Cells were treated with siRNA specific for a9nAChR or negative control siRNA and the cell extract was subjected to western blot for expression of galectin-3. The number on top of blot represents arbitrary unit showing quantification of the galectin-3 expression as measured by ImageJ software binding assay, STS alone induced apoptosis, which was reduced by almost fourfold when treated with nicotine plus STS (Fig. 4d) . Consistent with the cell viability study, galectin-3 siRNA (si-gal3) abrogated the effect of nicotine on STS-induced apoptosis (Fig. 4d) . Similar to the annexin V binding assay, nicotine reduced STS-induced DNA fragmentation of MCF-7 cells by almost 40 %, but galectin-3 siRNA or shRNA abrogated the effect of nicotine on STS-induced DNA fragmentation (Fig. 4e) .
To investigate the effect of nicotine and galectin-3 on mitochondrial permeability transition, cells were treated with staurosporine (1 lM) alone or in the presence or absence of nicotine (100 lM) or in the presence of nicotine plus galectin-3 siRNA for 24 h and stained with JC-1 dye. JC-1 accumulates in mitochondria in potential-dependent manner, as indicated by a fluorescence emission shift from green (527 nm) to red (590 nm) under normal conditions. Mitochondrial depolarization is indicated by a decrease in the red/green fluorescent intensity ratio. The potentialsensitive color shift is due to concentration-dependent formation of red fluorescence J-aggregates [40] . STSinduced loss of mitochondrial membrane potential as Fig. 4 Galectin-3 reduces apoptosis through promotion of mitochondrial stability. a Quantitative mRNA expression of galectin-3 in gene-specific or negative control siRNA treated MCF7 cells by RT-PCR. Relative mRNA expression based on GAPDH expression was calculated according to the comparative DDC(t) method. b Western blot showing galectin-3 expression in galectin-3 specific si RNA treated MCF-7 cells. c MCF7 cells were challenged with known apoptotic inducer staurosporine (1 lM) for 48 h and then role of nicotine (100 lM) and galectin-3 was examined through viability study using WST1. Role of galectin-3 was investigated using galectin-3 specific siRNA (si-gal3) and shRNA (sh-gal3). d Amount of annexin-V positive cells was measured by flow cytometry as described in the ''Methods'' section, and data were presented as percent of annexin-V positive cells. e STSinduced DNA fragmentation of cells in the presence of nicotine alone or nicotine plus siRNA (galectin-3 specific or negative control) was measured on a colorimetric assay as described in the ''Methods'' section. F. The mitochondrial membrane potential was measured using JC1 dye and data were represented as the ratio of the emission 590 (red): 527 (green). All bar graphs showing quantitative data were represented as ±SD. ***p B 0.001. NS not significant Breast Cancer Res Treat (2014) 145: 5-22 13 indicated by the F590/F527 ratio was 0.77 compared to 1.3 for control cells (p \ 0.001) (Fig. 4f) . However, galectin-3 siRNA significantly (p \ 0.001) abrogated the effect of nicotine on STS-induced loss of mitochondrial membrane potential (Fig. 4f) . Taken together these results suggest a positive role for galectin-3 in promoting the integrity of mitochondrial membrane potential.
Nicotine induces side population in MCF-7 cells
Side-population (SP) cells within cancer cells represent a small fraction and are known to enrich cancer stem-like cells [41] [42] [43] . In these cells, certain ATP-binding cassette (ABC) transporters, including ABCG2/BCRP, ABCB1/ MDR1, and ABCA3 can pump out or limit the intake of the fluorescent dyes such as Hoechst 33342 or DyeCycle Violet [41, 44] ; whereas the rest of the cancer cells retain the dye. Thus, SP cells are analyzed by flow cytometer Table 1 ) and smoked (5 patients) as determined by immunostaining with anti-TWIST1 antibody. Adjacent bar graph shows quantitative expression of TWIST1 in these samples. Each sample was performed in duplicate or in triplicate. The number of cells showing positive staining of TWIST1 was scored independently and blindly in three different area of each slide and then data were expressed as mean ± S.D, where ***p B 0.001. f Effect of TWIST1 silencing on SP. Cells were treated with nicotine or nicotine plus si-TWIST1 and SP was measured as described in a equipped with violet laser diode (VLD). DyeCycle Violet fluorescence is measured through blue and red band pass filter. DyeCycle Violet blue and red fluorescence are plotted allowing visualization of low fluorescence ''tail'' of cells (called ''Side Population'' cells) relative to the much larger bulk of DyeCycle Violet stained cells. SP of breast cancer cells has recently been shown to harbor stem celllike properties with resistance to apoptosis [34] [35] [36] . Consistent with this finding, the MCF-7 cell line was found to contain SP cells (5.9 %), which showed as a distinct ''tail'' in the flow cytometry scatter plot (Fig. 5a ). As inhibitors of ABC transporter are known to block SP population, we studied the effect of Verapamil on SP. As shown in Fig. 5a , Verapamil (50 lM) decreased the SP to 1.5 %. Nicotinetreated MCF-7 cells increased SP by 5.4-fold compared to untreated control cells (Fig. 5a, b) .
Effect of galectin-3 and TWIST1 on nicotine-induced side population in MCF-7 cells
To investigate the effect of galectin-3 on SP, MCF-7 cells were treated with nicotine plus galectin-3 siRNA (si-gal3).
The si-gal3 abrogated the effect of nicotine on SP by 2.4-fold suggesting the importance of galectin-3 on induction of SP (Fig. 5a, b) . To investigate if any other genes could be involved in inducing SP, RNA from nicotine-treated MCF-7 cells was screened for the expression for a few genes involved in cancer pathways including epithelial-tomesenchymal transition using a microarray. Notably, expression of TWIST1 was remarkably high (15-fold) ( Fig. 5c ; see also Table 2 ). This was corroborated by Western blot analysis as nicotine-treated cells showed higher amount of TWIST1 protein compared to the untreated cells (Fig. 5d ). Higher numbers of TWIST1 positive cells were present in the breast tumors of smokers compared to non-smokers (Fig. 5e) .
To investigate the effect of TWIST1 on SP, MCF-7 cells were treated with nicotine plus siRNA targeted to TWIST1. As shown in Fig. 5f , siRNA of TWIST1 reduced nicotineinduced SP by *2.8-fold % (p \ 0.001) suggesting the importance of TWIST1 for the existence of SP cells.
STAT3 modulates expression of galectin-3 and TWIST1
Since STAT3 is an important regulator of TWIST1 [45] , we investigated if nicotine treatment could induce STAT3 activation. In nicotine-treated cells, an increased pY 705 -STAT3 level was observed, with no change in the total STAT3-levels (Fig. 6a) . Consistent with this observation, higher numbers of pY 705 -STAT3 positive cells were found in the breast tumors derived from smokers than matching non-smokers (Fig. 6b) . We next tested the relevance of STAT3 to TWIST1 expression by RNAi-mediated silencing of STAT3. siRNA of STAT3 was first validated as the shRNA treated cells showed significant drop in STAT3 expression (Fig. 6c) . As shown in Fig. 6d , depleted of STAT3 (using 3 shRNAs) strongly suppressed the nicotine-induced expression of galectin-3 (Fig. 6e) suggesting a requirement for STAT3. Transcription factor binding site analyses of the LGALS3 promoter identified a potential STAT3 binding sequence (TTTCTGGGAA) from -2734 to -2725 bp (Fig. 6f) . A ChIP assay was then performed using STAT3 antibody to determine if STAT3 bound to the LGALS3 promoter in a nicotinedependent manner. As shown in Fig. 6g, LGALS3 promoter was detected in STAT3-ChIP product. The positive control promoter, TWIST1, was also detected in ChIP analyses (Fig. 6g) , since it is known to be a transcriptional target of STAT3 [45] . Neither LGALS3 nor TWIST1 was detected in the negative control (CHIP assay without STAT3 antibody) (data not shown).
STAT3 modulates nicotine-induced SP and antiapoptotic property in MCF-7 cells
Since STAT3 activation is required for galectin-3 expression, we investigated if silencing of STAT3 could influence on SP and apoptosis. Cells were treated with nicotine alone (100 lM, 48 h) or in the presence of sh1-STAT3 and analyzed the SP. As expected, nicotine-induced SP was significantly (p \ 0.001) reduced in presence of sh1-STAT3 (Fig. 7a) . We next analyzed apoptotic sensitivity of cells upon STS treatment in the presence of nicotine. As shown in Fig. 7b , nicotine reduced STS-induced cell death by *50 %, but silencing of STAT3 abrogated the effect of nicotine completely and promoted (72 %) cell death.
a9nAChR directly modulates STAT3 activation
To investigate if a9nAChR modulate STAT3 activation, a9nAChR was silenced in MCF7 cells using RNAi and STAT3 phosphorylation was analyzed. Knockdown of a9nAChR prevented nicotine-induced STAT3 activation (Fig. 8a) . We also studied the effect of a9nAChR silencing on cell viability and SP formation. As shown in Fig. 8b , nicotine prevented STS-induced cell death from 39 to 17 %. Silencing of a9nAChR abrogated the effect of nicotine completely and promoted cell death (48 %). Flow cytometry revealed that knockdown of a9nAChR reduced SP by 2.5-fold (p \ 0.001) compared nicotine alone (Fig. 8c) .
As SP cells are known to possess cancer stem-like property and are resistant to apoptosis [30] [31] [32] , we investigated mammosphere formation in untreated and nicotinetreated MCF-7 cells in absence or in the presence of various siRNAs. Nicotine-treated MCF-7 cells readily formed several mammospheres (Fig. 8d) , but si-RNAs specific for galectin-3, a9nAChR, TWIST1, and STAT3 strongly reduced formation of mammospheres (80-94 % reduction, p \ 0.001) (Fig. 8e) .
Discussion
Galectin-3 regulates multiple biological functions, such as cell proliferation, tumor progression and metastasis, and apoptosis [13] [14] [15] [16] 23] , but the detailed mechanisms of its effects and the corresponding signaling molecules are not well understood. Increased expression of galectin-3 in many cancers and its role in promotion of tumor growth and metastasis [17] [18] [19] [20] [21] [22] suggests that galectin-3 may serve as an attractive target for cancer therapy. In fact, a few studies on galectin-3 targeted therapy were performed to document therapeutic effects of synthetic carbohydratebased small molecule inhibitors of galectin-3 [26] [27] [28] [29] . Although the expression of galectin-3 in early stages of prostate cancer is slightly down-regulated by methylation of its promoter DNA [31, 46] , it promotes prostate cancer growth and metastasis possibly by modulating host immune system [16] . In this study, we show that expression of galectin-3 in breast cancer cells such as MCF-7 is modulated by nicotine or its receptor, a9nAChR. Nicotine- Fig. 7 STAT3 promotes nicotine-induced side population (SP) and cell viability. a MCF-7 cells were treated with nicotine (100 lM, 48 h) or nicotine plus sh1-STAT3 and SP was analyzed using Dye cycle violet dye (DCV). b Cell viability of the treated cells was studied using WST-1. In both cases, data were represented as ± SD, ***p B 0.001. Staurosporine was used as an apoptosis inducer induced up-regulation of galectin-3 might be involved in the promotion of stem cell property and apoptosis resistance.
Nicotine interacts with nAChR and functions in muscle or at the nervous system to elicit tobacco addiction [47, 48] . Among many isoforms of nAChR, a7nAChR has been linked to progression of many cancers [2] . However, recent reports suggest that a9nAChR is associated with the progression of breast cancer [6, 49] . Consistent with this report, we observed nicotine-induced up-regulation of a9nAChR, but not a7nAChR, in MCF-7 cells. Up-regulation of a9nAChR was also observed in breast cancers from patients, who were smokers compared to those from nonsmokers. Nicotine-dependent activation of MAPK and PI3K/Akt were reported as two important signaling pathways downstream to a9nAChR [49, 50] . These signaling pathways activate estrogen receptor, which then interacts with two other transcription factors AP1 and VDR and bind to the promoter of a9nAChR forming a strong positive feedback loop. In this study, we present a9nAChR-mediated STAT3 activation as a new signaling cascade in breast cancer cells exposed to nicotine. Microarray analyses of nicotine-treated MCF-7 cells for a few genes involved in cancer pathways, revealed a remarkable up-regulation of TWIST1. As STAT3 is an important transcription regulator of TWIST1, we investigated if nicotine treatment could b Cell viability of the treated cells was studied using WST-1. The data was represented as ±SD, ***p B 0.001. Staurosorine used as an apoptosis inducer. c Effect of a9nAChR silencing on SP. Cells were treated with nicotine (100 lM, 48 h) or nicotine plus si-a9nAChR and SP was measured using Dye cycle violet dye (DCV). d, e Effect of nicotine and silencing of various genes on mammosphere formation. MCF-7 cells were treated with siRNA targeted to each gene for 48 h. After washing, equal number of cells from each treatment was incubated in Mammocult medium for 48 h and spheres were counted. In d, a representative mammosphere that obtained from the nicotinetreated MCF-7 cells is shown cause STAT3 activation. Indeed, STAT3 was activated through a9nAChR in MCF-7 cells exposed to nicotine. However, nicotine-induced STAT3 activation through a7nAChR is known in other cancers such as pancreatic [4] and bladder [51] cancers. In pancreatic cancer, cigarettesmoke or nicotine causes up-regulation of MUC4 mucin via a7nAChR/JAK2/STAT3 pathway and promotes metastasis [4] .
In the cytokine signaling pathways, phosphorylation of STAT3 at Tyr 705 promotes its dimerization and translocation from the cytoplasm to nucleus [52] . In the nucleus, STAT3 binds to target genes and induces the transcription of several genes associated with cell proliferation and antiapoptosis [52, 53] . We have been working on the gene regulation and functional characterization of galectin-3 over the years [16, 31, 46, [54] [55] [56] . Several studies suggest that galectin-3 is involved in tumor cell adhesion, proliferation, angiogenesis, cancer progression, and metastasis [13, [16] [17] [18] [19] [20] . Moreover, intracellular galectin-3 suppresses drug induced apoptosis and anoikis [23, 57] . However, it is unknown if galectin-3 is regulated by a9nAChR or STAT3 in nicotine-induced cancer cells. Here, we showed that nicotine-induced a9nAChR activates STAT3 which induces the transcription of LGALS3 in MCF-7 breast cancer cells. We also found that galectin-3 prevents mitochondrial damage under conditions of chemotherapeutic challenge.
Recent studies suggest that side-population (SP) cells within cancer cells are enriched with cancer stem-like properties and are resistant to apoptosis [34] [35] [36] . Nicotine treatment of MCF-7 cells has recently been shown to increase cancer stem cell [58] , although the mechanisms are unclear. In our study, galectin-3 was found critical for the enrichment of nicotine-induced SP of MCF-7 cells. Moreover, expression of TWIST1 modulated by STAT3 enriched SP in MCF-7 cells. Drug-or chemo-resistance is also positively correlated with nicotine or cigarette smoke in many cancers [5, 10, [59] [60] [61] . For example, nicotineinduced chemo-resistance in non-small cell lung cancer (NSCLC) occurs through up-regulation of XIAP and surviving [5] . In lung cancer, nicotine induces chemo-resistance by modulating mitochondrial signaling [59] . In bladder cancer, nicotine-induced chemo-resistance is mediated by activation of STAT3 and down regulation of ERK1/2 via anchor and beta-adrenoceptors [10] . In this study, we present evidence that nicotine treatment induces expression of a9nAChR followed by activation of STAT3. Activated STAT3 directly binds to LGALS3 and TWIST1 promoters and induces transcriptional up-regulation of these genes resulting to delayed apoptosis and enriched SP of breast cancer cells.
Taken all together, a9nAChR acts as an upstream signaling molecule that modulates expression of galectin-3 through activation of STAT3 and manifest the functional significance of nicotine in progression of breast cancer (Fig. 9) . Thus, galectin-3 or its upstream signaling molecule STAT3 or a9nAChR could be potential target in suppressing nicotine-induced chemo-resistance in breast cancer. . Activated STAT3 migrates to nucleus and binds to the promoter of galectin-3 and TWIST1 resulting into transcriptional up-regulation of these genes
